| Year |
Citation |
Score |
| 2022 |
Tuval A, Brilon Y, Azogy H, Moskovitz Y, Leshkowitz D, Salame TM, Minden MD, Tal P, Rotter V, Oren M, Kaushansky N, Shlush LI. Pseudo-mutant P53 is a unique phenotype of -mutated pre-leukemia. Haematologica. PMID 35199506 DOI: 10.3324/haematol.2021.280329 |
0.362 |
|
| 2021 |
Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. Corrigendum to: The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. PMID 33991083 DOI: 10.1093/carcin/bgab028 |
0.809 |
|
| 2020 |
Stein Y, Aloni-Grinstein R, Rotter V. Mutant p53 oncogenicity - dominant-negative or gain-of-function? Carcinogenesis. PMID 33159515 DOI: 10.1093/carcin/bgaa117 |
0.45 |
|
| 2019 |
Koifman G, Aloni-Grinstein R, Rotter V. Corrigendum to 'p53 balances between tissue hierarchy and anarchy'. Journal of Molecular Cell Biology. 11: 1106. PMID 31881083 DOI: 10.1093/Jmcb/Mjz111 |
0.413 |
|
| 2019 |
Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. International Journal of Molecular Sciences. 20. PMID 31817996 DOI: 10.3390/Ijms20246197 |
0.555 |
|
| 2019 |
Stein Y, Aloni-Grinstein R, Rotter V. Mutant p53 - a potential player in shaping the tumor-stroma crosstalk. Journal of Molecular Cell Biology. PMID 31318969 DOI: 10.1093/Jmcb/Mjz071 |
0.484 |
|
| 2019 |
Charni-Natan M, Aloni-Grinstein R, Osher E, Rotter V. Liver and Steroid Hormones-Can a Touch of p53 Make a Difference? Frontiers in Endocrinology. 10: 374. PMID 31244779 DOI: 10.3389/Fendo.2019.00374 |
0.34 |
|
| 2019 |
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Retraction: Transactivation of the Gene Contributes to Mutant p53 Gain of Function. Cancer Research. 79: 2085. PMID 30987981 DOI: 10.1158/0008-5472.Can-19-0560 |
0.773 |
|
| 2019 |
Koifman G, Aloni-Grinstein R, Rotter V. p53 balances between tissue hierarchy and anarchy. Journal of Molecular Cell Biology. PMID 30925590 DOI: 10.1093/Jmcb/Mjz022 |
0.472 |
|
| 2019 |
Klug YA, Schwarzer R, Rotem E, Charni M, Nudelman A, Gramatica A, Zarmi B, Rotter V, Shai Y. The HIV gp41 fusion protein inhibits T cell activation through the lentiviral lytic peptide 2 motif. Biochemistry. PMID 30602116 DOI: 10.1021/Acs.Biochem.8B01175 |
0.319 |
|
| 2018 |
Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V. Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. Cell Death and Differentiation. PMID 30413783 DOI: 10.1038/S41418-018-0227-Z |
0.386 |
|
| 2018 |
Koifman G, Shetzer Y, Eizenberger S, Solomon H, Rotkopf R, Molchadsky A, Lonetto G, Goldfinger N, Rotter V. A mutant p53-dependent embryonic stem cell gene signature is associated with augmented tumorigenesis of stem cells. Cancer Research. PMID 30154152 DOI: 10.1158/0008-5472.Can-18-0805 |
0.799 |
|
| 2018 |
Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V. p53 and the Viral Connection: Back into the Future . Cancers. 10. PMID 29866997 DOI: 10.3390/Cancers10060178 |
0.312 |
|
| 2018 |
Charni-Natan M, Solomon H, Molchadsky A, Jacob-Berger A, Goldfinger N, Rotter V. Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner. Cell Death & Disease. 9: 647. PMID 29844359 DOI: 10.1038/S41419-018-0697-4 |
0.781 |
|
| 2018 |
Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, ... ... Rotter V, et al. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. PMID 29343849 DOI: 10.1038/S41388-017-0060-8 |
0.815 |
|
| 2018 |
Solomon H, Kogan I, Rotter V. Mutant p53 hinges between epithelial-mesenchymal transition and cancer stem cells Integrative Cancer Science and Therapeutics. 5. DOI: 10.15761/Icst.1000278 |
0.448 |
|
| 2017 |
Vyas P, Beno I, Xi Z, Stein Y, Golovenko D, Kessler N, Rotter V, Shakked Z, Haran TE. Diverse p53/DNA binding modes expand the repertoire of p53 response elements. Proceedings of the National Academy of Sciences of the United States of America. PMID 28912355 DOI: 10.1073/Pnas.1618005114 |
0.433 |
|
| 2017 |
Solomon H, Bräuning B, Fainer I, Ben-Nissan G, Rabani S, Goldfinger N, Moscovitz O, Shakked Z, Rotter V, Sharon M. Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. Cell Death and Differentiation. PMID 28885617 DOI: 10.1038/Cdd.2017.139 |
0.479 |
|
| 2017 |
Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy. Blood. PMID 28607134 DOI: 10.1182/Blood-2017-02-763086 |
0.807 |
|
| 2017 |
Molchadsky A, Rotter V. p53 and its mutants on the slippery road from stemness to carcinogenesis. Carcinogenesis. PMID 28334334 DOI: 10.1093/Carcin/Bgw092 |
0.811 |
|
| 2016 |
Grespi F, Landré V, Molchadsky A, Di Daniele N, Marsella LT, Melino G, Rotter V. Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells. Cell Death & Disease. 7: e2567. PMID 28032868 DOI: 10.1038/Cddis.2016.419 |
0.819 |
|
| 2016 |
Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, Rotter V. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors. International Journal of Cancer. PMID 28008605 DOI: 10.1002/Ijc.30554 |
0.792 |
|
| 2016 |
Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death and Differentiation. PMID 27768121 DOI: 10.1038/Cdd.2016.117 |
0.782 |
|
| 2016 |
Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, Elhanany E, Rotter V, Oren M, Zick Y. TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response. Cell Death and Differentiation. PMID 27740623 DOI: 10.1038/Cdd.2016.108 |
0.525 |
|
| 2016 |
Morel M, Shtrahman R, Rotter V, Nissim L, Bar-Ziv RH. Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. Proceedings of the National Academy of Sciences of the United States of America. PMID 27385823 DOI: 10.1073/Pnas.1604391113 |
0.344 |
|
| 2016 |
Oren M, Tal P, Rotter V. Targeting mutant p53 for cancer therapy. Aging. PMID 27347904 |
0.3 |
|
| 2016 |
Shetzer Y, Molchadsky A, Rotter V. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. Cold Spring Harbor Perspectives in Medicine. PMID 27235476 DOI: 10.1101/Cshperspect.A026203 |
0.811 |
|
| 2016 |
Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget. PMID 26943582 DOI: 10.18632/Oncotarget.7857 |
0.471 |
|
| 2016 |
Stein Y, Jacob A, Goldfinger N, Straussman R, Rotter V. Mutant p53 modulates the signal of hepatocyte growth factor (HGF) to endow cancer cells with drug resistance European Journal of Cancer. 61: S134. DOI: 10.1016/S0959-8049(16)61473-9 |
0.407 |
|
| 2015 |
Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death and Differentiation. PMID 26358154 DOI: 10.1038/Cdd.2015.119 |
0.825 |
|
| 2015 |
Rivlin N, Koifman G, Rotter V. p53 orchestrates between normal differentiation and cancer. Seminars in Cancer Biology. 32: 10-7. PMID 24406212 DOI: 10.1016/J.Semcancer.2013.12.006 |
0.455 |
|
| 2014 |
Charni M, Rivlin N, Molchadsky A, Aloni-Grinstein R, Rotter V. p53 in liver pathologies-taking the good with the bad. Journal of Molecular Medicine (Berlin, Germany). 92: 1229-34. PMID 25404244 DOI: 10.1007/S00109-014-1223-5 |
0.794 |
|
| 2014 |
Solomon H, Sharon M, Rotter V. Modulation of alternative splicing contributes to cancer development: Focusing on p53 isoforms, p53β and p53γ Cell Death and Differentiation. 21: 1347-1349. PMID 25109594 DOI: 10.1038/Cdd.2014.99 |
0.489 |
|
| 2014 |
Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, ... Rotter V, et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proceedings of the National Academy of Sciences of the United States of America. 111: 11145-50. PMID 25024203 DOI: 10.1073/Pnas.1404139111 |
0.573 |
|
| 2014 |
Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, ... ... Rotter V, et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death and Differentiation. 21: 1419-31. PMID 24832469 DOI: 10.1038/Cdd.2014.57 |
0.796 |
|
| 2014 |
Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proceedings of the National Academy of Sciences of the United States of America. 111: 7006-11. PMID 24778235 DOI: 10.1073/Pnas.1320428111 |
0.834 |
|
| 2014 |
Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V. The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis. 35: 1196-208. PMID 24658181 DOI: 10.1093/Carcin/Bgu073 |
0.81 |
|
| 2014 |
Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A. The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells. Bmc Cancer. 14: 158. PMID 24598028 DOI: 10.1186/1471-2407-14-158 |
0.332 |
|
| 2014 |
Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: the barrier to cancer stem cell formation. Febs Letters. 588: 2580-9. PMID 24560790 DOI: 10.1016/J.Febslet.2014.02.011 |
0.405 |
|
| 2014 |
Hellem MR, Olsen JR, Hua Y, Qu Y, Marvyin K, Rostad K, Liu J, Li L, Rotter V, Lin B, Ke X, Oyan AM, Kalland K. Abstract 2329: Restriction of androgen receptor and target gene expression Cancer Research. 74: 2329-2329. DOI: 10.1158/1538-7445.Am2014-2329 |
0.339 |
|
| 2014 |
Rotter V. 42: The mutant p53-cancer stem cells and drug resistance paradigm European Journal of Cancer. 50: S11. DOI: 10.1016/S0959-8049(14)50042-1 |
0.305 |
|
| 2013 |
Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V. p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer & Metabolism. 1: 9. PMID 24280180 DOI: 10.1186/2049-3002-1-9 |
0.487 |
|
| 2013 |
Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'--more than meets the eye. Trends in Molecular Medicine. 19: 447-53. PMID 23769623 DOI: 10.1016/J.Molmed.2013.05.004 |
0.371 |
|
| 2013 |
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 23: 634-46. PMID 23680148 DOI: 10.1016/J.Ccr.2013.03.022 |
0.474 |
|
| 2013 |
Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. Plos One. 8: e62547. PMID 23658742 DOI: 10.1371/Journal.Pone.0062547 |
0.493 |
|
| 2013 |
Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta Plos One. 8. PMID 23630584 DOI: 10.1371/Journal.Pone.0061353 |
0.538 |
|
| 2013 |
Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death and Differentiation. 20: 774-83. PMID 23412343 DOI: 10.1038/Cdd.2013.9 |
0.801 |
|
| 2013 |
Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V. Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis. 34: 190-8. PMID 23054612 DOI: 10.1093/Carcin/Bgs318 |
0.543 |
|
| 2013 |
Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V. p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death and Differentiation. 20: 312-20. PMID 22996684 DOI: 10.1038/Cdd.2012.125 |
0.833 |
|
| 2012 |
Leibovich-Rivkin T, Buganim Y, Solomon H, Meshel T, Rotter V, Ben-Baruch A. Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. Cancers. 4: 55-76. PMID 24213226 DOI: 10.3390/Cancers4010055 |
0.4 |
|
| 2012 |
Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nature Genetics. 44: 1207-14. PMID 23064413 DOI: 10.1038/Ng.2442 |
0.713 |
|
| 2012 |
Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P. Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology. 153: 4633-43. PMID 22903612 DOI: 10.1210/En.2012-1348 |
0.306 |
|
| 2012 |
Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. Journal of Cell Science. 125: 5578-86. PMID 22899716 DOI: 10.1242/Jcs.106815 |
0.839 |
|
| 2012 |
Goldstein I, Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends in Endocrinology and Metabolism: Tem. 23: 567-75. PMID 22819212 DOI: 10.1016/J.Tem.2012.06.007 |
0.41 |
|
| 2012 |
Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N, Rotter V. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. Journal of Cell Science. 125: 3144-52. PMID 22427690 DOI: 10.1242/Jcs.099663 |
0.846 |
|
| 2012 |
Kravchenko-Balasha N, Levitzki A, Goldstein A, Rotter V, Gross A, Remacle F, Levine RD. On a fundamental structure of gene networks in living cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 4702-7. PMID 22392990 DOI: 10.1073/Pnas.1200790109 |
0.342 |
|
| 2012 |
Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. p53, a novel regulator of lipid metabolism pathways. Journal of Hepatology. 56: 656-62. PMID 22037227 DOI: 10.1186/1753-6561-6-S3-P61 |
0.812 |
|
| 2012 |
Olsen JR, Ke X, Rostad K, Hellem MR, Qu Y, Lin B, Lorens JB, Micklem DR, Haugen H, Gravdal K, Halvorsen OJ, Akslen LA, Rotter V, Oyan AM, Kalland KH. Abstract 1290: The ability of the transcription factor p63 to induce selected gene expression modules associated with mesenchymal to epithelial transition of prostate cells Cancer Research. 72: 1290-1290. DOI: 10.1158/1538-7445.Am2012-1290 |
0.478 |
|
| 2011 |
Madar S, Goldstein I, Neeman O, Rotter V. Beyond tumor suppression: p53 controls blastocyst implantation. Cell Cycle (Georgetown, Tex.). 10: 4203. PMID 22157227 DOI: 10.4161/Cc.10.24.18412 |
0.362 |
|
| 2011 |
Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death and Differentiation. 19: 180-3. PMID 22095277 DOI: 10.1038/Cdd.2011.148 |
0.517 |
|
| 2011 |
Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. The Journal of Pathology. 225: 475-8. PMID 22025211 DOI: 10.1002/Path.2988 |
0.518 |
|
| 2011 |
Buganimy Y, Madary S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V. Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression Carcinogenesis. 32: 1749-1757. PMID 21900211 DOI: 10.1093/Carcin/Bgr203 |
0.81 |
|
| 2011 |
Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & Cancer. 2: 466-74. PMID 21779514 DOI: 10.1177/1947601911408889 |
0.542 |
|
| 2011 |
Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. Plos One. 6: e21650. PMID 21747944 DOI: 10.1371/Journal.Pone.0021650 |
0.363 |
|
| 2011 |
Madar S, Solomon H, Rotter V. Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants. Cell Cycle (Georgetown, Tex.). 10: 2248-9. PMID 21670601 DOI: 10.4161/Cc.10.14.15933 |
0.401 |
|
| 2011 |
Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development (Cambridge, England). 138: 1827-38. PMID 21447558 DOI: 10.1242/Dev.053645 |
0.807 |
|
| 2011 |
Kravchenko-Balasha N, Remacle F, Gross A, Rotter V, Levitzki A, Levine RD. Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. Bmc Systems Biology. 5: 42. PMID 21410932 DOI: 10.1186/1752-0509-5-42 |
0.338 |
|
| 2011 |
Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. Omics : a Journal of Integrative Biology. 15: 305-12. PMID 21332394 DOI: 10.1089/Omi.2010.0084 |
0.84 |
|
| 2011 |
Madar S, Stambolsky P, Rotter V. Unleash the wild type: restoration of p53 suppressive activity in skin cancer. Cell Cycle (Georgetown, Tex.). 10: 736-7. PMID 21311232 DOI: 10.4161/Cc.10.5.14928 |
0.797 |
|
| 2011 |
Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Molecular and Cellular Biology. 31: 1679-89. PMID 21300779 DOI: 10.1128/Mcb.01072-10 |
0.827 |
|
| 2011 |
Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. Plos One. 6: e14632. PMID 21297939 DOI: 10.1371/Journal.Pone.0014632 |
0.343 |
|
| 2011 |
Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 317: 234-47. PMID 20969863 DOI: 10.1016/J.Yexcr.2010.10.009 |
0.356 |
|
| 2011 |
Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies Cancer Gene Therapy. 18: 2-11. PMID 20966976 DOI: 10.1038/Cgt.2010.63 |
0.573 |
|
| 2011 |
Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, ... ... Rotter V, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death and Differentiation. 18: 271-81. PMID 20689556 DOI: 10.1038/Cdd.2010.94 |
0.851 |
|
| 2011 |
Olsen JR, Ke X, Qu Y, Rostad K, Hellem MR, Lorens JB, Micklem DR, Haugen H, Gravdal K, Halvorsen OJ, Rotter V, Akslen LA, Oyan AM, Kalland KH. Abstract 3089: The role of p63 regulation during epithelial to mesenchymal transition (EMT) and subsequent accumulation of malignant features of primary immortalized prostate cells Cancer Research. 71: 3089-3089. DOI: 10.1158/1538-7445.Am2011-3089 |
0.517 |
|
| 2011 |
Sarig R, Rotter V. Editorial: Can an iPS cell secure its genomic fidelity Cell Death and Differentiation. 18: 743-744. DOI: 10.1038/Cdd.2011.14 |
0.374 |
|
| 2010 |
Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, Øyan AM, Kalland KH. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. Bmc Genomics. 11: 669. PMID 21108828 DOI: 10.1186/1471-2164-11-669 |
0.317 |
|
| 2010 |
Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. The Journal of Experimental Medicine. 207: 2127-40. PMID 20696700 DOI: 10.1084/Jem.20100797 |
0.836 |
|
| 2010 |
Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discovery Medicine. 9: 448-54. PMID 20515613 |
0.326 |
|
| 2010 |
Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis. 31: 1501-8. PMID 20504879 DOI: 10.1093/Carcin/Bgq101 |
0.826 |
|
| 2010 |
Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R, Rotter V. p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss. Febs Letters. 584: 2473-7. PMID 20434500 DOI: 10.1016/J.Febslet.2010.04.058 |
0.821 |
|
| 2010 |
Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, ... Rotter V, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. Plos One. 5: e9657. PMID 20300178 DOI: 10.1371/Journal.Pone.0009657 |
0.794 |
|
| 2010 |
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 17: 273-85. PMID 20227041 DOI: 10.1016/J.Ccr.2009.11.025 |
0.817 |
|
| 2010 |
Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, ... ... Rotter V, et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Research. 70: 2274-84. PMID 20197462 DOI: 10.1158/0008-5472.Can-09-2661 |
0.832 |
|
| 2010 |
Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology. 2: a001107. PMID 20182618 DOI: 10.1101/Cshperspect.A001107 |
0.55 |
|
| 2010 |
Brosh R, Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Molecular Biosystems. 6: 17-29. PMID 20024063 DOI: 10.1039/B911416E |
0.412 |
|
| 2010 |
Ke X, Li W, Qu Y, Hovland R, Liu R, Rotter V, Akslen LA, Oyan AM, Kalland K. Abstract 2465: Gene expression, phenotypic and karyotypic analyses of stepwise prostate carcinogenesisin vitro Cancer Research. 70: 2465-2465. DOI: 10.1158/1538-7445.Am10-2465 |
0.363 |
|
| 2010 |
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53 (DOI:10.1016/j.ccr.2009.11.025) Cancer Cell. 17: 523. DOI: 10.1016/J.Ccr.2010.04.017 |
0.798 |
|
| 2009 |
Lavelin I, Beer A, Kam Z, Rotter V, Oren M, Navon A, Geiger B. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. Plos One. 4: e8503. PMID 20041034 DOI: 10.1371/Journal.Pone.0008503 |
0.372 |
|
| 2009 |
Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation Oncogene. 28: 4469-4479. PMID 19855428 DOI: 10.1038/Onc.2009.270 |
0.469 |
|
| 2009 |
Goldstein I, Rotter V. Mutations in the tetramerization domain of p53: more than just keeping monomers apart. Cell Cycle (Georgetown, Tex.). 8: 3259-60. PMID 19823022 DOI: 10.4161/Cc.8.20.10077 |
0.409 |
|
| 2009 |
Buganim Y, Rotter V. p53: balancing tumour suppression and implications for the clinic. European Journal of Cancer (Oxford, England : 1990). 45: 217-34. PMID 19775621 DOI: 10.1016/S0959-8049(09)70037-1 |
0.568 |
|
| 2009 |
Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews. Cancer. 9: 701-13. PMID 19693097 DOI: 10.1038/Nrc2693 |
0.494 |
|
| 2009 |
Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Molecular Cancer Research : McR. 7: 1212-23. PMID 19671672 DOI: 10.1158/1541-7786.Mcr-09-0073 |
0.357 |
|
| 2009 |
Zemach A, Paul LK, Stambolsky P, Efroni I, Rotter V, Grafi G. The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity. Experimental Cell Research. 315: 3554-62. PMID 19647732 DOI: 10.1016/J.Yexcr.2009.07.022 |
0.756 |
|
| 2009 |
Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. International Journal of Cancer. Journal International Du Cancer. 125: 2810-9. PMID 19544527 DOI: 10.1002/Ijc.24669 |
0.397 |
|
| 2009 |
Yuan J, Yang BM, Zhong ZH, Shats I, Milyavsky M, Rotter V, Lock RB, Reddel RR, MacKenzie KL. Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene. 28: 2678-89. PMID 19483728 DOI: 10.1038/Onc.2009.136 |
0.396 |
|
| 2009 |
Peller S, Tabach Y, Rotschild M, Garach-Joshua O, Cohen Y, Goldfinger N, Rotter V. Identification of gene networks associated with erythroid differentiation. Blood Cells, Molecules & Diseases. 43: 74-80. PMID 19329339 DOI: 10.1016/J.Bcmd.2009.01.020 |
0.336 |
|
| 2009 |
Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. Plos One. 4: e4687. PMID 19262738 DOI: 10.1371/Journal.Pone.0004687 |
0.334 |
|
| 2009 |
Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, Schalken JA, Rotter V. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 30: 698-705. PMID 19233959 DOI: 10.1093/Carcin/Bgp043 |
0.732 |
|
| 2009 |
Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene. 28: 933-6. PMID 19060923 DOI: 10.1038/Onc.2008.445 |
0.553 |
|
| 2009 |
Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Journal of Molecular Biology. 385: 249-65. PMID 18996393 DOI: 10.1016/J.Jmb.2008.10.063 |
0.4 |
|
| 2009 |
Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 30: 20-7. PMID 18842679 DOI: 10.1093/Carcin/Bgn232 |
0.379 |
|
| 2008 |
Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, ... ... Rotter V, et al. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Molecular Systems Biology. 4: 229. PMID 19034270 DOI: 10.1038/Msb.2008.65 |
0.344 |
|
| 2008 |
Marrazzo E, Marchini S, Tavecchio M, Alberio T, Previdi S, Erba E, Rotter V, Broggini M. The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. European Journal of Cancer (Oxford, England : 1990). 45: 443-53. PMID 19008096 DOI: 10.1016/J.Ejca.2008.09.024 |
0.47 |
|
| 2008 |
Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. Plos One. 3: e3707. PMID 19002260 DOI: 10.1371/Journal.Pone.0003707 |
0.789 |
|
| 2008 |
Ke XS, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Øyan AM, Kalland KH. Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. Plos One. 3: e3368. PMID 18852876 DOI: 10.1371/Journal.Pone.0003368 |
0.358 |
|
| 2008 |
Salah Z, Haupt S, Maoz M, Baraz L, Rotter V, Peretz T, Haupt Y, Bar-Shavit R. p53 controls hPar1 function and expression. Oncogene. 27: 6866-74. PMID 18820708 DOI: 10.1038/Onc.2008.324 |
0.592 |
|
| 2008 |
Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (Georgetown, Tex.). 7: 1870-9. PMID 18594199 DOI: 10.4161/Cc.7.12.6161 |
0.534 |
|
| 2008 |
Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network Cell Cycle. 7: 3291. DOI: 10.4161/Cc.7.21.7256 |
0.366 |
|
| 2007 |
Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Molecular and Cellular Biology. 27: 8228-42. PMID 17875924 DOI: 10.1128/Mcb.00374-07 |
0.799 |
|
| 2007 |
Tang X, Milyavsky M, Goldfinger N, Rotter V. Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene. 26: 7302-12. PMID 17533371 DOI: 10.1038/Sj.Onc.1210542 |
0.713 |
|
| 2007 |
Shats I, Milyavsky M, Cholostoy A, Brosh R, Rotter V. Myocardin in tumor suppression and myofibroblast differentiation. Cell Cycle (Georgetown, Tex.). 6: 1141-6. PMID 17495540 DOI: 10.4161/Cc.6.10.4251 |
0.447 |
|
| 2007 |
Efrati S, Berman S, Goldfinger N, Erez N, Averbukh Z, Golik A, Rotter V, Weissgarten J. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. Journal of Hypertension. 25: 1041-52. PMID 17414669 DOI: 10.1097/Hjh.0B013E32807Fb09C |
0.324 |
|
| 2007 |
Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53 Oncogene. 26: 2202-2211. PMID 17401429 DOI: 10.1038/Sj.Onc.1210294 |
0.568 |
|
| 2007 |
Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Research. 67: 2396-401. PMID 17363555 DOI: 10.1158/0008-5472.Can-06-2425 |
0.531 |
|
| 2007 |
Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, ... ... Rotter V, et al. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell. 11: 133-46. PMID 17292825 DOI: 10.1016/J.Ccr.2006.11.022 |
0.81 |
|
| 2006 |
Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Research. 66: 10750-9. PMID 17108111 DOI: 10.1158/0008-5472.Can-06-0916 |
0.847 |
|
| 2006 |
Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V. Regulation of AIF expression by p53. Cell Death and Differentiation. 13: 2140-9. PMID 16729031 DOI: 10.1038/Sj.Cdd.4401965 |
0.842 |
|
| 2006 |
Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 25: 359-69. PMID 16170349 DOI: 10.1038/Sj.Onc.1209061 |
0.837 |
|
| 2005 |
Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A, Mantovani R, Domany E, Rotter V, Pilpel Y. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology. 1: 2005.0022. PMID 16729057 DOI: 10.1038/Msb4100030 |
0.498 |
|
| 2005 |
Orgad S, Goldfinger N, Cohen G, Rotter V, Solomon B. Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. Febs Letters. 579: 5609-15. PMID 16213502 DOI: 10.1016/J.Febslet.2005.09.031 |
0.539 |
|
| 2005 |
Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Research. 65: 4530-43. PMID 15930270 DOI: 10.1158/0008-5472.Can-04-3880 |
0.586 |
|
| 2005 |
Damalas A, Weis L, Nordgard S, Kristensen V, Gardner K, Cheng G, Gelinas C, Levrero M, Strano S, Børresen-Dale A, Rotter V, Oren M, Blandino G. Mutant p53 exerts its gain of function through activation of the NF-κB pathway Breast Cancer Research. 7. DOI: 10.1186/Bcr1176 |
0.527 |
|
| 2004 |
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Research. 64: 8318-27. PMID 15548700 DOI: 10.1158/0008-5472.Can-04-1145 |
0.855 |
|
| 2004 |
Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. The Journal of Biological Chemistry. 279: 50976-85. PMID 15371422 DOI: 10.1074/Jbc.M402502200 |
0.86 |
|
| 2004 |
Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 23: 5759-69. PMID 15208672 DOI: 10.1038/Sj.Onc.1207706 |
0.729 |
|
| 2004 |
Erez N, Stambolsky P, Shats I, Milyavsky M, Kachko T, Rotter V. Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. Febs Letters. 567: 311-5. PMID 15178343 DOI: 10.1016/J.Febslet.2004.05.003 |
0.763 |
|
| 2004 |
Meerson A, Milyavsky M, Rotter V. p53 mediates density-dependent growth arrest Febs Letters. 559: 152-158. PMID 14960324 DOI: 10.1016/S0014-5793(04)00027-4 |
0.508 |
|
| 2004 |
Matas D, Milyavsky M, Shats I, Nissim L, Goldfinger N, Rotter V. p53 is a regulator of macrophage differentiation. Cell Death and Differentiation. 11: 458-67. PMID 14713961 DOI: 10.1038/Sj.Cdd.4401379 |
0.805 |
|
| 2004 |
Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 25: 11-9. PMID 14555612 DOI: 10.1093/Carcin/Bgg186 |
0.845 |
|
| 2003 |
Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. The Journal of Clinical Investigation. 112: 1887-94. PMID 14679184 DOI: 10.1172/Jci19757 |
0.78 |
|
| 2003 |
Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC, Rotter V. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Research. 63: 7147-57. PMID 14612508 |
0.563 |
|
| 2003 |
Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene. 22: 5667-76. PMID 12944915 DOI: 10.1038/Sj.Onc.1206724 |
0.821 |
|
| 2003 |
Peller S, Frenkel J, Lapidot T, Kahn J, Rahimi-Levene N, Yona R, Nissim L, Goldfinger N, Sherman DJ, Rotter V. The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts. Oncogene. 22: 4648-55. PMID 12879009 DOI: 10.1038/Sj.Onc.1206541 |
0.491 |
|
| 2003 |
Shats I, Milyavsky M, Erez N, Rotter V. The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein. Febs Letters. 546: 321-4. PMID 12832061 DOI: 10.1016/S0014-5793(03)00607-0 |
0.418 |
|
| 2003 |
Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Human Mutation. 21: 277-84. PMID 12619113 DOI: 10.1002/Humu.10190 |
0.499 |
|
| 2003 |
Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America. 100: 143-8. PMID 12518062 DOI: 10.1073/Pnas.0237083100 |
0.844 |
|
| 2002 |
Herkel J, Modrow JP, Bamberger S, Kanzler S, Rotter V, Cohen IR, Lohse AW. Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis. Autoimmunity. 35: 493-6. PMID 12765474 DOI: 10.1080/0891693021000054075 |
0.332 |
|
| 2002 |
Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene. 21: 8223-31. PMID 12447685 DOI: 10.1038/Sj.Onc.1206137 |
0.449 |
|
| 2002 |
Erez N, Milyavsky M, Goldfinger N, Peles E, Gudkov AV, Rotter V. Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene. 21: 6713-21. PMID 12360397 DOI: 10.1038/Sj.Onc.1205867 |
0.346 |
|
| 2002 |
Shakked Z, Yavnilovitch M, Kalb Gilboa AJ, Kessler N, Wolkowicz R, Rotter V, Haran TE. DNA binding and 3'-5' exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene. 21: 5117-26. PMID 12140762 DOI: 10.1038/Sj.Onc.1205667 |
0.423 |
|
| 2002 |
Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells Cancer Investigation. 20: 509-517. PMID 12094546 DOI: 10.1081/Cnv-120002151 |
0.487 |
|
| 2002 |
Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis. 23: 1025-32. PMID 12082025 DOI: 10.1093/Carcin/23.6.1025 |
0.813 |
|
| 2001 |
Milyavsky M, Mimran A, Senderovich S, Zurer I, Erez N, Shats I, Goldfinger N, Cohen I, Rotter V. Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Research. 29: 5207-15. PMID 11812854 DOI: 10.1093/Nar/29.24.5207 |
0.848 |
|
| 2001 |
Uberti D, Piccioni L, Cadei M, Grigolato P, Rotter V, Memo M. p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following γ-irradiation Molecular Brain Research. 93: 81-89. PMID 11532341 DOI: 10.1016/S0169-328X(01)00180-2 |
0.506 |
|
| 2001 |
Sigal A, Matas D, Almog N, Goldfinger N, Rotter V. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene. 20: 4891-8. PMID 11521201 DOI: 10.1038/Sj.Onc.1204724 |
0.806 |
|
| 2001 |
Herkel J, Mimran A, Erez N, Kam N, Lohse AW, Märker-Hermann E, Rotter V, Cohen IR. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. Journal of Autoimmunity. 17: 63-9. PMID 11488638 DOI: 10.1006/Jaut.2001.0518 |
0.342 |
|
| 2001 |
Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The Embo Journal. 20: 4163-72. PMID 11483519 DOI: 10.1093/Emboj/20.15.4163 |
0.838 |
|
| 2001 |
Almog N, Milyavsky M, Stambolsky P, Falcovitz A, Goldfinger N, Rotter V. The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis. 22: 779-85. PMID 11323398 DOI: 10.1093/Carcin/22.5.779 |
0.835 |
|
| 2001 |
Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V. Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene. 20: 581-9. PMID 11313990 DOI: 10.1038/Sj.Onc.1204120 |
0.846 |
|
| 2001 |
Seluanov A, Gorbunova V, Falcovitz A, Sigal A, Milyavsky M, Zurer I, Shohat G, Goldfinger N, Rotter V. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Molecular and Cellular Biology. 21: 1552-64. PMID 11238892 DOI: 10.1128/Mcb.21.5.1552-1564.2001 |
0.847 |
|
| 2001 |
Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Research. 61: 88-96. PMID 11196204 |
0.83 |
|
| 2000 |
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research. 60: 6788-93. PMID 11156366 |
0.495 |
|
| 2000 |
Lilling G, Hacohen H, Nordenberg J, Livnat T, Rotter V, Sidi Y. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio? Cancer Letters. 161: 27-34. PMID 11078910 DOI: 10.1016/S0304-3835(00)00579-6 |
0.331 |
|
| 2000 |
Almog N, Goldfinger N, Rotter V. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53 Oncogene. 19: 3395-3403. PMID 10918596 DOI: 10.1038/Sj.Onc.1203673 |
0.545 |
|
| 2000 |
Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, Schwartz D, Rotter V, Dekel N, Cohen-Armon M. A fast signal-induced activation of poly(ADP-ribose) polymerase: A novel downstream target of phospholipase C Journal of Cell Biology. 150: 293-307. PMID 10908573 DOI: 10.1083/Jcb.150.2.293 |
0.325 |
|
| 2000 |
Herkel J, Erez-Alon N, Mimran A, Wolkowicz R, Harmelin A, Ruiz P, Rotter V, Cohen IR. Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. European Journal of Immunology. 30: 977-84. PMID 10760784 DOI: 10.1002/(Sici)1521-4141(200004)30:4<977::Aid-Immu977>3.0.Co;2-A |
0.353 |
|
| 1999 |
Yaron Y, Schwartz D, Evans MI, Aloni R, Kapon A, Rotter V. p53 Tumor suppresser gene expression in the mouse ovary during an artificially induced ovulatory cycle Journal of Reproductive Medicine For the Obstetrician and Gynecologist. 44: 107-114. PMID 10853441 |
0.4 |
|
| 1999 |
Zhao W, He C, Rotter V, Merrick BA, Selkirk JK. An intragenic deletion of nuclear localization signal-1 of p53 tumor suppressor gene results in loss of apoptosis in murine fibroblasts. Cancer Letters. 147: 101-8. PMID 10660095 DOI: 10.1016/S0304-3835(99)00283-9 |
0.571 |
|
| 1999 |
Schwartz D, Goldfinger N, Kam Z, Rotter V. p53 Controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis Cell Growth and Differentiation. 10: 665-675. PMID 10547070 |
0.396 |
|
| 1999 |
Tendler Y, Weisinger G, Coleman R, Diamond E, Lischinsky S, Kerner H, Rotter V, Zinder O. Tissue-specific p53 expression in the nervous system. Brain Research. Molecular Brain Research. 72: 40-6. PMID 10521597 DOI: 10.1016/S0169-328X(99)00202-8 |
0.522 |
|
| 1999 |
Uberti D, Schwartz D, Almog N, Goldfinger N, Harmelin A, Memo M, Rotter V. Epithelial cells of different organs exhibit distinct patterns of p53- dependent and p53-independent apoptosis following DNA insult Experimental Cell Research. 252: 123-133. PMID 10502405 DOI: 10.1006/Excr.1999.4606 |
0.508 |
|
| 1999 |
Torchinsky A, Ivnitsky I, Savion S, Shepshelovich J, Gorivodsky M, Fein A, Carp H, Schwartz D, Frankel J, Rotter V, Toder V. Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo. Teratogenesis, Carcinogenesis, and Mutagenesis. 19: 353-67. PMID 10495452 DOI: 10.1002/(Sici)1520-6866(1999)19:5<353::Aid-Tcm5>3.0.Co;2-0 |
0.43 |
|
| 1999 |
Frenkel J, Sherman D, Fein A, Schwartz D, Almog N, Kapon A, Goldfinger N, Rotter V. Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress. Oncogene. 18: 2901-7. PMID 10362261 DOI: 10.1038/Sj.Onc.1202518 |
0.527 |
|
| 1999 |
Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. Febs Letters. 450: 197-204. PMID 10359074 DOI: 10.1016/S0014-5793(99)00505-0 |
0.798 |
|
| 1999 |
Oren M, Rotter V. Introduction. p53: The first twenty years Cellular and Molecular Life Sciences. 55: 9-11. PMID 10065147 DOI: 10.1007/S000180050265 |
0.557 |
|
| 1999 |
Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin Molecular Brain Research. 65: 167-175. PMID 10064887 DOI: 10.1016/S0169-328X(98)00339-8 |
0.544 |
|
| 1999 |
Zhou X, Wang XW, Xu L, Hagiwara K, Nagashima M, Wolkowicz R, Zurer I, Rotter V, Harris CC. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research. 59: 843-8. PMID 10029073 |
0.866 |
|
| 1998 |
Almog N, Rotter V. An insight into the life of p53: A protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998 Biochimica Et Biophysica Acta - Reviews On Cancer. 1378. PMID 9875245 DOI: 10.1016/S0304-419X(98)00024-9 |
0.45 |
|
| 1998 |
Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16: 3269-77. PMID 9681825 DOI: 10.1038/Sj.Onc.1201867 |
0.82 |
|
| 1998 |
Prokocimer M, Peller S, Ben-Bassat H, Goldfinger N, Rotter V. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (Loucy) with t(16:20) and 5q- chromosomal aberrations Leukemia and Lymphoma. 29: 607-611. PMID 9643574 DOI: 10.3109/10428199809050920 |
0.429 |
|
| 1998 |
Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies Human Mutation. 12: 4-18. PMID 9633814 DOI: 10.1002/(Sici)1098-1004(1998)12:1<4::Aid-Humu2>3.0.Co;2-G |
0.445 |
|
| 1998 |
Ruiz PJ, Wolkowicz R, Waisman A, Hirschberg DL, Carmi P, Erez N, Garren H, Herkel J, Karpuj M, Steinman L, Rotter V, Cohen IR. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Medicine. 4: 710-2. PMID 9623981 DOI: 10.1038/Nm0698-710 |
0.442 |
|
| 1998 |
Wolkowicz R, Peled A, Elkind NB, Rotter V. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus Cancer Detection and Prevention. 22: 1-13. PMID 9466043 DOI: 10.1046/J.1525-1500.1998.00003.X |
0.45 |
|
| 1997 |
Schwartz D, Rotter V. p53-dependent cell cycle control: Response to genotoxic stress Seminars in Cancer Biology. 8: 325-336. PMID 10101798 DOI: 10.1006/Scbi.1998.0095 |
0.534 |
|
| 1997 |
Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V. Role of wild type p53 in the G2 phase: Regulation of the γ-irradiation-induced delay and DNA repair Oncogene. 15: 2597-2607. PMID 9399647 DOI: 10.1038/Sj.Onc.1201436 |
0.519 |
|
| 1997 |
Almog N, Rotter V. Involvement of p53 in cell differentiation and development Biochimica Et Biophysica Acta - Reviews On Cancer. 1333. PMID 9294016 DOI: 10.1016/S0304-419X(97)00012-7 |
0.602 |
|
| 1997 |
Rotter V, Ronen D. Expression of p53 in differentiation and apoptosis and its deregulation in tumor cell Leukemia. 11: 327-330. PMID 9209380 |
0.475 |
|
| 1997 |
Sthoeger Z, Evron E, Goland S, Shani A, Wolkowicz R, Goldfinger N, Rotter V, Fogel M. Anti-p53 autoantibodies in colon cancer patients. Annals of the New York Academy of Sciences. 815: 496-8. PMID 9186708 DOI: 10.1111/J.1749-6632.1997.Tb52113.X |
0.396 |
|
| 1997 |
Simons A, Melamed-Bessudo C, Wolkowicz R, Sperling J, Sperling R, Eisenbach L, Rotter V. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene. 14: 145-55. PMID 9010216 DOI: 10.1038/Sj.Onc.1200825 |
0.436 |
|
| 1997 |
Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfinger N, Pei H, Rotter V. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Molecular and Cellular Biology. 17: 713-22. PMID 9001225 DOI: 10.1128/Mcb.17.2.713 |
0.504 |
|
| 1996 |
Reisman D, Bálint E, Loging WT, Rotter V, Almon E. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells Genomics. 38: 364-370. PMID 8975713 DOI: 10.1006/Geno.1996.0639 |
0.431 |
|
| 1996 |
Peled A, Schwartz D, Elkind NB, Wolkowicz R, Li R, Rotter V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells Oncogene. 13: 1677-1685. PMID 8895513 |
0.477 |
|
| 1996 |
Schreiber L, Sharabi Y, Schwartz D, Goldfinger N, Brodie C, Rotter V, Shoham J. Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells Scandinavian Journal of Immunology. 44: 314-322. PMID 8845023 DOI: 10.1046/J.1365-3083.1996.D01-312.X |
0.402 |
|
| 1996 |
Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels Cell Growth and Differentiation. 7: 21-30. PMID 8788030 |
0.477 |
|
| 1996 |
Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells Molecular and Cellular Biology. 16: 5178-5185. PMID 8756675 DOI: 10.1128/Mcb.16.9.5178 |
0.508 |
|
| 1996 |
Peled A, Zipori D, Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells Cancer Research. 56: 2148-2156. PMID 8616864 |
0.414 |
|
| 1995 |
Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility Dna and Cell Biology. 14: 983-990. PMID 8534372 DOI: 10.1089/Dna.1995.14.983 |
0.349 |
|
| 1995 |
Aloni-Grinstein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon γ-irradiation induces a G2 arrest-dependent immunoglobulin κ light chain gene expression Embo Journal. 14: 1392-1401. PMID 7729417 |
0.456 |
|
| 1995 |
Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. Direct involvement of p53 in programmed cell death of oligodendrocytes Embo Journal. 14: 1136-1144. PMID 7720704 DOI: 10.1002/J.1460-2075.1995.Tb07097.X |
0.454 |
|
| 1995 |
Elkind NB, Goldfinger N, Rotter V. Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats Oncogene. 11: 841-851. PMID 7675445 |
0.324 |
|
| 1995 |
Wolkowicz R, Peled A, Elkind NB, Rotter V. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form Proceedings of the National Academy of Sciences of the United States of America. 92: 6842-6846. PMID 7624329 DOI: 10.1073/Pnas.92.15.6842 |
0.46 |
|
| 1995 |
Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors Molecular Carcinogenesis. 13: 166-172. PMID 7619219 DOI: 10.1002/Mc.2940130306 |
0.402 |
|
| 1995 |
Barak Y, Lupo A, Zauberman A, Juven T, Aloni-Grinstein R, Gottlieb E, Rotter V, Oren M. Targets for transcriptional activation by wild-type p53: endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene. Cold Spring Harbor Symposia On Quantitative Biology. 59: 225-35. PMID 7587074 DOI: 10.1101/Sqb.1994.059.01.027 |
0.448 |
|
| 1995 |
Tendler Y, Schwartz Y, Reshef R, Shasha SM, Rotter V, Shkolnik T. Immunohistochemical detection of p53 protein expression in HPV-induced condyloma acuminatum Acta Dermato-Venereologica. 75: 177-179. PMID 7544519 DOI: 10.2340/0001555575177179 |
0.388 |
|
| 1995 |
Wolkowicz R, Elkind NB, Ronen D, Rotter V. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes Oncogene. 10: 1167-1174. PMID 7535417 |
0.338 |
|
| 1995 |
Aloni-Grinstein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. The Embo Journal. 14: 1392-1401. DOI: 10.1002/J.1460-2075.1995.Tb07125.X |
0.544 |
|
| 1994 |
Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages Blood. 84: 2391-2411. PMID 7919359 DOI: 10.1182/Blood.V84.8.2391.Bloodjournal8482391 |
0.471 |
|
| 1993 |
Schwartz D, Goldfinger N, Rotter V. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes Oncogene. 8: 1487-1494. PMID 8502474 |
0.429 |
|
| 1993 |
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif Cell Growth &Amp; Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 4: 57-65. PMID 8494784 |
0.339 |
|
| 1993 |
Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif Oncogene. 8: 1183-1193. PMID 8479742 |
0.458 |
|
| 1993 |
Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene Nucleic Acids Research. 21: 345-350. PMID 8441640 DOI: 10.1093/Nar/21.2.345 |
0.527 |
|
| 1993 |
Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein Molecular and Cellular Biology. 13: 1378-1384. PMID 8441383 DOI: 10.1128/Mcb.13.3.1378 |
0.453 |
|
| 1993 |
Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer A, Donehower LA, Levine AJ. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proceedings of the National Academy of Sciences of the United States of America. 90: 9075-9. PMID 8415656 DOI: 10.1073/Pnas.90.19.9075 |
0.488 |
|
| 1993 |
Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage Oncogene. 8: 3297-3305. PMID 8247532 |
0.458 |
|
| 1993 |
Almon E, Goldfinger N, Kapon A, Schwartz D, Levine AJ, Rotter V. Testicular tissue-specific expression of the p53 suppressor gene Developmental Biology. 156: 107-116. PMID 7680625 DOI: 10.1006/Dbio.1993.1062 |
0.508 |
|
| 1993 |
Rotter V, Foord O, Navot N. In search of the functions of normal p53 protein Trends in Cell Biology. 3: 46-49. DOI: 10.1016/0962-8924(93)90151-P |
0.553 |
|
| 1993 |
Rotter V. The p53 suppressor gene plays a role in cell differentiation European Journal of Cancer. 29: S24. DOI: 10.1016/0959-8049(93)90721-Q |
0.491 |
|
| 1992 |
Ronen D, Teitz Y, Goldfinger N, Rotter V. Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses Nucleic Acids Research. 20: 3435-3441. PMID 1630914 DOI: 10.1093/Nar/20.13.3435 |
0.49 |
|
| 1991 |
Rotter V, Prokocimer M. p53 And human malignancies Advances in Cancer Research. 57: 257-272. PMID 1950705 DOI: 10.1016/S0065-230X(08)61001-5 |
0.556 |
|
| 1991 |
Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro Proceedings of the National Academy of Sciences of the United States of America. 88: 8982-8986. PMID 1924360 DOI: 10.1073/Pnas.88.20.8982 |
0.508 |
|
| 1991 |
Foord OS, Bhattacharya P, Reich Z, Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein Nucleic Acids Research. 19: 5191-5198. PMID 1923804 DOI: 10.1093/Nar/19.19.5191 |
0.446 |
|
| 1991 |
Ronen D, Rotter V, Reisman D. Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif Proceedings of the National Academy of Sciences of the United States of America. 88: 4128-4132. PMID 1851994 DOI: 10.1073/Pnas.88.10.4128 |
0.495 |
|
| 1991 |
Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization Cell Growth &Amp; Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 2: 661-667. PMID 1809377 |
0.433 |
|
| 1991 |
Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein Oncogene. 6: 2055-2065. PMID 1719467 |
0.433 |
|
| 1991 |
Shaulsky G, Rotter V, Goldfinger N. Alterations in Tumor Development in Vivo Mediated by Expression of Wild Type or Mutant p53 Proteins Cancer Research. 51: 5232-5237. PMID 1717142 |
0.452 |
|
| 1990 |
Shaulsky G, Ben-Ze'ev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells Oncogene. 5: 1707-1711. PMID 2267137 |
0.408 |
|
| 1990 |
Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis Molecular and Cellular Biology. 10: 6565-6577. PMID 2247074 DOI: 10.1128/Mcb.10.12.6565 |
0.483 |
|
| 1989 |
Reisman D, Rotter V. Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells Oncogene. 4: 945-953. PMID 2668845 |
0.334 |
|
| 1989 |
Reisman D, Rotter V. Induced expression from the Moloney murine leukemia virus long terminal repeat during differentiation of human myeloid cells is mediated through its transcriptional enhancer Molecular and Cellular Biology. 9: 3571-3575. PMID 2477690 DOI: 10.1128/Mcb.9.8.3571 |
0.373 |
|
| 1989 |
Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia [see comments] Blood. 74: 2318-2324. DOI: 10.1182/Blood.V74.7.2318.2318 |
0.382 |
|
| 1988 |
Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V. p53 increases experimental metastatic capacity of murine carcinoma cells Molecular and Cellular Biology. 8: 2078-2081. PMID 3290647 DOI: 10.1128/Mcb.8.5.2078 |
0.472 |
|
| 1988 |
Reisman D, Greenberg M, Rotter V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1 Proceedings of the National Academy of Sciences of the United States of America. 85: 5146-5150. PMID 2839831 DOI: 10.1073/Pnas.85.14.5146 |
0.467 |
|
| 1987 |
Shohat O, Greenberg M, Reisman D, Oren M, Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense Oncogene. 1: 277-283. PMID 2455263 |
0.44 |
|
| 1986 |
Nicolson GL, LaBiche RA, Frazier ML, Blick M, Tressler RJ, Reading CL, Irimura T, Rotter V. Differential expression of metastasis-associated cell surface glycoproteins and mRNA in a murine large cell lymphoma Journal of Cellular Biochemistry. 31: 305-312. PMID 3760037 DOI: 10.1002/Jcb.240310408 |
0.403 |
|
| 1986 |
Prokocimer M, Shaklai M, Ben Bassat H, Wolf D, Goldfinger N, Rotter V. Expression of p53 in human leukemia and lymphoma Blood. 68: 113-118. PMID 3521760 DOI: 10.1182/Blood.V68.1.113.Bloodjournal681113 |
0.506 |
|
| 1986 |
Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. Molecular basis for heterogeneity of the human p53 protein Molecular and Cellular Biology. 6: 4650-4656. PMID 3025664 DOI: 10.1128/Mcb.6.12.4650 |
0.45 |
|
| 1986 |
Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, Rotter V. Immunologically distinct p53 molecules generated by alternative splicing Molecular and Cellular Biology. 6: 3232-3239. PMID 3023970 DOI: 10.1128/Mcb.6.9.3232 |
0.505 |
|
| 1986 |
Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Phillip Koeffler H. Human p53 gene localized to short arm of chromosome 17 Nature. 319: 783-784. PMID 3005871 DOI: 10.1038/319783A0 |
0.398 |
|
| 1985 |
Rotter V, Wolf D, Blick M, Nicolson GL. Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma Clinical &Amp; Experimental Metastasis. 3: 77-86. PMID 4042463 DOI: 10.1007/Bf01758957 |
0.416 |
|
| 1985 |
Rotter V, Wolf D. Biological and molecular analysis of p53 cellular-encoded tumor antigen Advances in Cancer Research. 43: 113-141. PMID 3887856 DOI: 10.1016/S0065-230X(08)60944-6 |
0.512 |
|
| 1985 |
Wolf D, Laver-Rudich Z, Rotter V. In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene Molecular and Cellular Biology. 5: 1887-1893. PMID 3018534 |
0.394 |
|
| 1985 |
Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells Proceedings of the National Academy of Sciences of the United States of America. 82: 790-794. PMID 2858093 DOI: 10.1073/Pnas.82.3.790 |
0.556 |
|
| 1985 |
Wolf D, Harris N, Goldfinger N, Rotter V. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule Molecular and Cellular Biology. 5: 127-132. PMID 2580227 DOI: 10.1128/Mcb.5.1.127 |
0.514 |
|
| 1984 |
Rotter V, Wolft D, Nicolson GL. The expression of transformation-related protein p53 and p53-containing mRNA in murine RAW117 large cell lymphoma cells of differing metastatic potential Clinical &Amp; Experimental Metastasis. 2: 199-204. PMID 6399697 DOI: 10.1007/Bf00132926 |
0.515 |
|
| 1984 |
Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 312: 649-51. PMID 6390217 DOI: 10.1038/312649A0 |
0.389 |
|
| 1984 |
Rotter V, Wolf D, Pravtcheva D, Ruddle FH. Chromosomal assignment of the murine gene encoding the transformation-related protein p53 Molecular and Cellular Biology. 4: 383-385. PMID 6366521 DOI: 10.1128/Mcb.4.2.383 |
0.468 |
|
| 1984 |
Wolf D, Admon S, Oren M, Rotter V. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species Molecular and Cellular Biology. 4: 552-558. PMID 6144042 DOI: 10.1128/Mcb.4.3.552 |
0.503 |
|
| 1984 |
Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences Molecular and Cellular Biology. 4: 1402-1410. PMID 6095069 DOI: 10.1128/Mcb.4.7.1402 |
0.507 |
|
| 1984 |
Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene Cell. 38: 119-126. PMID 6088057 DOI: 10.1016/0092-8674(84)90532-4 |
0.526 |
|
| 1983 |
Rotter V, Abutbul H, Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts Embo Journal. 2: 1041-1047. PMID 6354706 DOI: 10.1002/J.1460-2075.1983.Tb01543.X |
0.425 |
|
| 1983 |
Rotter V, Abutbul H, Wolf D. The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice International Journal of Cancer. 31: 315-320. PMID 6298128 DOI: 10.1002/Ijc.2910310311 |
0.498 |
|
| 1983 |
Rotter V, Friedman H, Katz A, Zerivitz K, Wolf D. Variation in antigenic determinants of p53 transformation-related protein obtained from various species Journal of Immunology. 131: 329-333. PMID 6190914 |
0.359 |
|
| 1983 |
Rotter V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells Proceedings of the National Academy of Sciences of the United States of America. 80: 2613-2617. PMID 6189126 DOI: 10.1073/Pnas.80.9.2613 |
0.457 |
|
| 1981 |
Rotter V, Boss MA, Baltimore D. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents Journal of Virology. 38: 336-346. PMID 6264107 DOI: 10.1128/Jvi.38.1.336-346.1981 |
0.337 |
|
| 1980 |
Rotter V, Witte ON, Coffman R, Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50 Journal of Virology. 36: 547-555. PMID 6159484 DOI: 10.1128/Jvi.36.2.547-555.1980 |
0.368 |
|
| 1979 |
Rotter V, Yakir Y, Trainin N. Role of L-alanine in the response of human lymphocytes to PHA and Con A Journal of Immunology. 123: 1726-1731. PMID 573302 |
0.519 |
|
| 1979 |
Zaizov R, Vogel R, Wolach B, Cohen IJ, Varsano I, Shohat B, Handzel Z, Rotter V, Yakir Y, Trainin N. The effect of THF in lymphoproliferative and myeloproliferative diseases in children. Annals of the New York Academy of Sciences. 332: 172-83. PMID 294830 DOI: 10.1111/J.1749-6632.1979.Tb47110.X |
0.511 |
|
| 1979 |
Rotter V, Trainin N. Role of thymic hormone (THF) and of a thymic plasma recirculating factor (TPRF) in the modulation of human lymphocyte response to PHA and Con A Journal of Immunology. 122: 414-420. PMID 216747 |
0.519 |
|
| 1979 |
Trainin N, Rotter V, Yakir Y, Leve R, Handzel Z, Shohat B, Zaizov R. Biochemical and biological properties of THF in animal and human models Annals of the New York Academy of Sciences. 332: 9-22. PMID 43694 DOI: 10.1111/J.1749-6632.1979.Tb47093.X |
0.527 |
|
| 1979 |
Zaizov R, Vogel R, Wolach B, Shohat B, Handzel Z, Yakir V, Rotter V, Trainin N. 39 THE EFFECT OF THE IN IMMUNOSUPPRESSED CHILDREN WITH LYMPHO PROLIFERATIVE DISEASES Pediatric Research. 13: 954-954. DOI: 10.1203/00006450-197908000-00055 |
0.537 |
|
| 1978 |
Rotter V, Fink A, Trainin N. In vitro allogeneic response of human lymphocytes dependent upon dialyzable plasma components and a thymic hormone, THF Cellular Immunology. 36: 242-250. PMID 147137 DOI: 10.1016/0008-8749(78)90268-X |
0.551 |
|
| 1977 |
Rotter V, Trainin N. Effect of thymic hormone on the response of different lymphoid cell populations to T mitogens Israel Journal of Medical Sciences. 13: 363-370. PMID 301520 |
0.563 |
|
| 1977 |
Zaizov R, Vogel R, Cohen I, Varsano I, Shohat B, Rotter V, Trainin N. Thymic hormone (THF) therapy in immunosuppressed children with lymphoproliferative neoplasia and generalized varicella Biomedicine Express. 27: 105-108. PMID 268220 |
0.495 |
|
| 1977 |
Varsano I, Schonfeld TM, Matoth Y, Shohat B, Englander T, Rotter V, Trainin N. Severe disseminated adenovirus infection successfully treated with a thymic humoral factor, THF. Acta Paediatrica Scandinavica. 66: 329-31. PMID 194457 DOI: 10.1111/J.1651-2227.1977.Tb07902.X |
0.552 |
|
| 1976 |
Rotter V, Trainin N. Depletion of suppressor T cells in syngeneic chimeric mice Advances in Experimental Medicine and Biology. 66: 593-598. PMID 1083656 DOI: 10.1007/978-1-4613-4355-4_92 |
0.6 |
|
| 1976 |
Rotter V, Schlesinger M, Kalderon R, Trainin N. Response of human lymphocytes to PHA and Con A, dependent on and regulated by THF, a thymic hormone Journal of Immunology. 117: 1927-1932. PMID 993589 |
0.524 |
|
| 1975 |
Rotter V, Trainin N. Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells Transplantation. 20: 68-74. PMID 1101476 DOI: 10.1097/00007890-197507000-00011 |
0.601 |
|
| 1975 |
Rotter V, Trainin N. Increased mitogenic reactivity of normal spleen cells to T lectins induced by thymus humoral factor (THF) Cellular Immunology. 16: 413-421. PMID 1090382 DOI: 10.1016/0008-8749(75)90130-6 |
0.595 |
|
| 1975 |
Rotter V, Trainin N. Proceedings: Increased mitogenic reactivity of lymphoid cells to T lectins induced by thymus humoral factor Israel Journal of Medical Sciences. 11: 1381-1382. PMID 1082875 |
0.536 |
|
| 1975 |
Rotter V, Trainin N. Elimination of suppressor T-cells in mice undergoing a graft-versus-host reaction expressed by increased response to polyvinylpyrrolidone (PVP) Cellular Immunology. 18: 199-209. PMID 237632 DOI: 10.1016/0008-8749(75)90048-9 |
0.588 |
|
| 1974 |
Rotter V, Trainin N. Thymus cell population exerting a regulatory function in the immune response of mice to polyvinyl pyrrolidone Cellular Immunology. 13: 76-86. PMID 4615810 DOI: 10.1016/0008-8749(74)90228-7 |
0.591 |
|
| 1974 |
Trainin N, Levo Y, Rotter V. Resistance to hydrocortisone conferred upon thymocytes by a thymic humoral factor European Journal of Immunology. 4: 634-637. PMID 4154201 DOI: 10.1002/Eji.1830040913 |
0.577 |
|
| 1973 |
Globerson A, Rotter V, Nakamura I, Trainin N. Thymus extracts induce differentiation of thymus derived cells. Advances in Experimental Medicine and Biology. 29: 183-9. PMID 4605385 DOI: 10.1007/978-1-4615-9017-0_27 |
0.605 |
|
| 1973 |
Rotter V, Globerson A, Nakamura I, Trainin N. Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. The Journal of Experimental Medicine. 138: 130-42. PMID 4577615 DOI: 10.1084/Jem.138.1.130 |
0.596 |
|
| 1973 |
Lonai P, Mogilner B, Rotter V, Trainin N. Studies on the effect of a thymic humoral factor on differentiation of thymus derived lymphocytes European Journal of Immunology. 3: 21-26. PMID 4146225 DOI: 10.1002/Eji.1830030106 |
0.601 |
|
| Show low-probability matches. |
